[go: up one dir, main page]

AR024703A1 - Benzazepinonas y quinazolinas - Google Patents

Benzazepinonas y quinazolinas

Info

Publication number
AR024703A1
AR024703A1 ARP000103542A ARP000103542A AR024703A1 AR 024703 A1 AR024703 A1 AR 024703A1 AR P000103542 A ARP000103542 A AR P000103542A AR P000103542 A ARP000103542 A AR P000103542A AR 024703 A1 AR024703 A1 AR 024703A1
Authority
AR
Argentina
Prior art keywords
cell
well
quinazolinas
benzazepinonas
dhesive
Prior art date
Application number
ARP000103542A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR024703A1 publication Critical patent/AR024703A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los compuestos de la formula (1) así como también las sales y ésteres de los mismos que pueden utilizarse farmacéuticamente, donde R1, R2, X, Y, Z y ptienen el significado que se proporciona en la reivindicacion 1, inhiben la union de las proteínasa dhesivas a la superficie de diferentes tipos de células y,de acuerdo con ello, influye en las interacciones célula-célula y célula-matriz. Se los puede utilizar en la forma de preparaciones farmacéuticas para eltratamiento o la prevencion deneoplasm as, metástasis tumoral, desarrollo tumoral, osteoporosis, enfermedad de Paget, retinopatía diabética, degeneracionmacular, restenosis posterior a una intervencion vascular, psoriasis, artritis, fibrosis e insuficiencia renal así comotambién para la infeccion causada porvirus, bacterias u hongos.
ARP000103542A 1999-07-13 2000-07-11 Benzazepinonas y quinazolinas AR024703A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99113708 1999-07-13

Publications (1)

Publication Number Publication Date
AR024703A1 true AR024703A1 (es) 2002-10-23

Family

ID=8238595

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103542A AR024703A1 (es) 1999-07-13 2000-07-11 Benzazepinonas y quinazolinas

Country Status (4)

Country Link
US (1) US6506744B1 (es)
AR (1) AR024703A1 (es)
AU (1) AU5826100A (es)
WO (1) WO2001004103A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060025388A1 (en) * 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
MXPA01011052A (es) * 1999-04-30 2002-11-22 Univ Michigan Aplicaciones terapeuticas de benzodiazepinas pro-apoctoticas.
US7276348B2 (en) * 1999-04-30 2007-10-02 Regents Of The University Of Michigan Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof
US7572788B2 (en) 1999-04-30 2009-08-11 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20040176358A1 (en) * 1999-04-30 2004-09-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20030119029A1 (en) * 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
US20050113460A1 (en) * 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
AU5826100A (en) 1999-07-13 2001-01-30 F. Hoffmann-La Roche Ag Benzazepinones and quinazolines
PL370176A1 (en) 2001-11-13 2005-05-16 3-Dimensional Pharmaceuticals, Inc. Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
MXPA04011557A (es) 2002-05-23 2005-07-05 Chiron Corp Compuestos de quinazolinona sustituida.
US7439249B2 (en) * 2002-12-31 2008-10-21 Vertex Pharmaceuticals Incorporated Inhibitors of phosphatases
CA2511925C (en) * 2002-12-31 2012-11-13 Vertex Pharmaceuticals Incorporated Heterocyclic inhibitors of phosphatases, compositions and uses thereof
US20040142950A1 (en) * 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors
EP1651229A1 (en) * 2003-05-23 2006-05-03 Chiron Corporation Guanidino-substituted quinazolinone compounds as mc4-r agonists
US20050272723A1 (en) * 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20060052369A1 (en) * 2004-09-07 2006-03-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
WO2006074358A1 (en) * 2005-01-03 2006-07-13 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
EP1893218A4 (en) 2005-06-01 2011-01-12 Univ Michigan UNLOCKED BENZODIAZEPINE COMPOSITIONS AND METHOD
US20070105844A1 (en) * 2005-10-26 2007-05-10 Regents Of The University Of Michigan Therapeutic compositions and methods
CA2628193C (en) 2005-11-01 2012-08-14 The Regents Of The University Of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
US8034822B2 (en) * 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
US7759338B2 (en) * 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
AU2007258468B2 (en) 2006-06-09 2011-09-22 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US7851465B2 (en) 2007-03-09 2010-12-14 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
AU2008298870C1 (en) 2007-09-14 2014-10-09 The Regents Of The University Of Michigan F1F0-ATPase inhibitors and related methods
NZ584842A (en) 2007-11-06 2012-06-29 Univ Michigan Benzodiazepinone compounds useful in the treatment of skin conditions, in particular, psoriasis
JP5567573B2 (ja) 2008-09-11 2014-08-06 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン アリールグアニジンｆ１ｆ０−ａｔｐアーゼ阻害剤およびそれと関連する方法
WO2010121164A2 (en) 2009-04-17 2010-10-21 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
EP2470020A4 (en) 2009-09-18 2013-03-13 Univ Michigan BENZODIAZEPINONE COMPOUNDS AND TREATMENT METHODS THEREWITH
WO2011062765A2 (en) 2009-11-17 2011-05-26 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
AU2010322287B2 (en) 2009-11-17 2014-04-03 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
JP6164610B2 (ja) * 2013-08-26 2017-07-19 国立大学法人東京農工大学 アミノ酸イソニトリル骨格を有する水中付着生物の防汚剤
WO2016019588A1 (en) * 2014-08-08 2016-02-11 The Broad Institute, Inc. Oxacazone compounds to treat clostridium difficile
JP2020509082A (ja) * 2017-02-10 2020-03-26 セレックス・オンコロジー・イノヴェーションズ・リミテッド がんの治療及び転移の抑制
CN111995576A (zh) * 2020-08-31 2020-11-27 三峡大学 多取代含氮杂环化合物的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2112360A1 (en) * 1991-06-28 1993-12-23 William Edward Bondinell Bicyclic fibrinogen antagonists
US5250679A (en) * 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
IT1254884B (it) * 1992-04-16 1995-10-11 Italfarmaco Spa Benzossazinoni e benzotiazinoni ad attivita' cardiovascolare
US5877278A (en) * 1992-09-24 1999-03-02 Chiron Corporation Synthesis of N-substituted oligomers
US5493020A (en) * 1993-07-29 1996-02-20 Genentech, Inc. Tricyclic inhibitors of the GPIIb IIIa receptor
CA2241633A1 (en) * 1995-12-29 1997-07-10 William Henry Miller Vitronectin receptor antagonists
KR20040084945A (ko) * 1996-07-25 2004-10-06 바이오겐 아이덱 엠에이 인코포레이티드 세포 유착 억제제
JP2001521522A (ja) * 1997-04-15 2001-11-06 ジェネンテック，インコーポレーテッド 新規なハロ−アルコキシカルボニルプロドラッグ
US6100282A (en) 1998-01-02 2000-08-08 Hoffman-La Roche Inc. Thiazole derivatives
EP0928790B1 (en) 1998-01-02 2003-03-05 F. Hoffmann-La Roche Ag Thiazole derivatives
AU5826100A (en) 1999-07-13 2001-01-30 F. Hoffmann-La Roche Ag Benzazepinones and quinazolines

Also Published As

Publication number Publication date
WO2001004103A1 (en) 2001-01-18
US6506744B1 (en) 2003-01-14
AU5826100A (en) 2001-01-30

Similar Documents

Publication Publication Date Title
AR024703A1 (es) Benzazepinonas y quinazolinas
ES2193471T3 (es) Derivados de tiazol.
ECSP034460A (es) Nuevos compuestos heterociclicos, su preparacion y su utilizacion como medicamentos, en especial como antibacterianos
BR0111457A (pt) Derivados de acilfeniluréia, processos para a sua preparação e sua aplicação como medicamentos
GT200000183A (es) Aminoacidos biciclicos como agentes farmaceuticos.
ES2194030T3 (es) Procedimiento para la preparacion de acido l-glutamico mediante fermentacion.
BR0203644A (pt) Derivados heteroarìlicos dissubstituìdos com ácido como inibidores de metaloproteinase de matriz
NZ580226A (en) Dimer compounds as inhibitors of iap
BR0015477A (pt) Soluções contendo epinastina
BRPI0512139A (pt) derivados tetraidro-2h-isoquinolin-1-ona substituìdos, método para sua produção e uso do mesmo como medicamento
AR029456A1 (es) Forma triturada
BR0311347A (pt) Alcanóis bis-aromáticos
BRPI0608178A2 (pt) derivados de aminopirazol, sua fabricação, composição farmacêutica e uso como agentes farmacêuticos
Hwu et al. New nordihydroguaiaretic acid derivatives as anti-HIV agents
BRPI0416005A (pt) tiazolidinonas, na preparação e utilização como medicamento
AR023058A1 (es) Derivados del tiazol, un procedimiento para su obtencion, composiciones farmaceuticas que los comprenden y el empleo de los mismos para la preparacion demedicamentos
MEP54208A (en) Medicaments containing steroids and a novel anticholinesterase drug
BRPI0518907A2 (pt) compostos, processo para a sua manufatura, composiÇÕes farmacÊuticas que os compreendem, mÉtodo para o tratamento e/ou prevenÇço de enfermidades que estço associadas com a modulaÇço de receptores de h3 e sua utilizaÇço
UY29896A1 (es) Nuevos derivados de cromano, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
BR0016780A (pt) Derivados de piperazina substituìdos, preparação dos mesmos e seu uso como medicamentos
BR0316500A (pt) N-alquinil-2-(fenóxi substituìdas)alquilamidas e seu uso como fungicidas
ES2176895T3 (es) Derivados de tiazol.
ECSP993185A (es) Derivados de tiazol
ECSP982811A (es) Derivados de tiazol
SE0402507D0 (sv) Medicinsk lösning, förfarande för framställning och användning därav